Background: We sought to identify the independent prognostic factors for survival of the patients with advanced lung adenocarcinoma who respond to first-line tyrosine kinase inhibitor (TKI) and receive radiotherapy Method: Patients with stage III and IV lung adenocarcinoma who responded to first-line TKI and received radiotherapy in West China Hospital from Dec 1, 2007 to Jan, 1, 2018 were retrospectively enrolled. Univariate and multivariate analysis for prognostic factors including gender, age, stage, brain metastasis status, EGFR mutation type, radiotherapy type, duration between TKI and the staring of radiotherapy, biological equivalent dose (BED) of radiotherapy, and progression status before radiotherapy were analyzed by Cox regression model. Radiation-associated PFS (rPFS) was defined as the date of beginning of radiotherapy to the date of newly disease progression. Results: Forty-five patients were enrolled in this study and 8 of them received radiotherapy combined with TKI before progression. Among the patients with progression disease, 17 of them received radiotherapy with continuation of TKI, 20 patients were treated with radiochemotherapy and ceased the use of TKI after progression. The median follow-up for all patients was 58.3 month. The median rPFS was 5.4 month (95%CI: 4.4-6.4). The results of univariate analysis showed that higher BED (HR¼0.460, 95%CI: 0.239-0.886, P ¼0.020) and radiotherapy prescribed before disease progression (HR¼0.354, 95%CI: 0.135 -0.927, P ¼0.034) was relevant to longer rPFS. Multivariate analysis revealed that BED (HR¼0.464, 95%CI: 0.240-0.899, P ¼0.023) and progression status before radiotherapy (HR¼0.357, 95%CI: 0.135-0.940, P ¼0.037) were independent predicators for rPFS. No difference of rPFS was found between the patients with conventional radiotherapy or stereotactic body radiation therapy (SBRT) (P¼0.450). The median overall survival (OS) was . Patients with advanced stage (HR¼3.749, 95%CI: 0.883 -15.919, P ¼0.073) and shorter duration between TKI and the staring of radiotherapy (HR¼1.962, 95%CI: 0.892-4.317, P ¼0.094) tend to have a shorter OS but without statistical significance. Conclusion: BED of radiotherapy and progression status were independent prognostic factor for rPFS. These results suggested the potential benefit of aggressive radiotherapy for patients with TKI treatment. Keywords: radiotherapy, TKI, lung adenocarcinoma 
Background: We sought to identify the independent prognostic factors for survival of the patients with advanced lung adenocarcinoma who respond to first-line tyrosine kinase inhibitor (TKI) and receive radiotherapy Method: Patients with stage III and IV lung adenocarcinoma who responded to first-line TKI and received radiotherapy in West China Hospital from Dec 1, 2007 to Jan, 1, 2018 were retrospectively enrolled. Univariate and multivariate analysis for prognostic factors including gender, age, stage, brain metastasis status, EGFR mutation type, radiotherapy type, duration between TKI and the staring of radiotherapy, biological equivalent dose (BED) of radiotherapy, and progression status before radiotherapy were analyzed by Cox regression model. Radiation-associated PFS (rPFS) was defined as the date of beginning of radiotherapy to the date of newly disease progression. Results: Forty-five patients were enrolled in this study and 8 of them received radiotherapy combined with TKI before progression. Among the patients with progression disease, 17 of them received radiotherapy with continuation of TKI, 20 patients were treated with radiochemotherapy and ceased the use of TKI after progression. The median follow-up for all patients was 58.3 month. The median rPFS was 5.4 month (95%CI: 4.4-6.4). The results of univariate analysis showed that higher BED (HR¼0.460, 95%CI: 0.239-0.886, P ¼0.020) and radiotherapy prescribed before disease progression (HR¼0.354, 95%CI: 0.135 -0.927, P ¼0.034) was relevant to longer rPFS. Multivariate analysis revealed that BED (HR¼0.464, 95%CI: 0.240-0.899, P ¼0.023) and progression status before radiotherapy (HR¼0.357, 95%CI: 0.135-0.940, P ¼0.037) were independent predicators for rPFS. No difference of rPFS was found between the patients with conventional radiotherapy or stereotactic body radiation therapy (SBRT) (P¼0.450). The median overall survival (OS) was 43.3 month (95%CI: 29.7-56.9). Patients with advanced stage (HR¼3.749, 95%CI: 0.883 -15.919, P ¼0.073) and shorter duration between TKI and the staring of radiotherapy (HR¼1.962, 95%CI: 0.892-4.317, P ¼0.094) tend to have a shorter OS but without statistical significance. Conclusion: BED of radiotherapy and progression status were independent prognostic factor for rPFS. These results suggested the potential benefit of aggressive radiotherapy for patients with TKI treatment. Keywords: radiotherapy, TKI, lung adenocarcinoma Background: Identifying patients at high risk for recurrence in resected non-small cell lung cancer (NSCLC) is the key to choose patients who can benefit from postoperative adjuvant therapy. However, the criteria to stratify patients to receive postoperative adjuvant therapy is still clinicopathologic factor-oriented such as differentiation, tumor size, the presence of pleural involvement and vascular invasion and so on. Even using adjuvant treatment under these criteria, 5 -year survival rate is around 60% even in earlystage disease. Here, we extracted potential candidate genes for stratifying resected NSCLC patients according to correlation with their survival using public big data and validated the prognostic role of the extracted candidate gene in tumor samples of patients' cohort with resected NSCLC. In TCGA database, we found 21 regulatory genes and 38 prognosisrelated-gene pairs in lung adenocarcinoma. Among them, VEGFC-ITGA5 pair was suggested to be relevant to tumorigenesis in the previous studies. In tumour tissues of 111 patients of resected NSCLC, the expression of ITGA5 was statistically correlated with that of VEGFC (P ¼ 0.015). In the patients with low expression of ITGA5, disease-free survival was longer than that in those with high expression (79.4 months vs 59.1 months, P ¼ 0.049) Conclusion: lITGA5 which affects VEGFC might one of the potential biomarkers relevant prognosis in patients with resected lung adenocarcinoma. Keyword: integrin subunit alpha 5, lung adenocarcinoma, VEGFC Results: Overall, expression was unpredictable and more than half of the protein domains could not be produced using any of the constructs. Here we described a novel fusion expression system based on mouse TEM7 (tumor endothelial marker 7), which could facilitate protein expression. With this approach we could produce all but one of the tumor marker domains that could not otherwise be expressed. In addition, we demonstrated that the tumor associated antigen hFZD10 produced as a fusion protein with mTEM7 could be used to enrich scFv antibodies from a yeast display library. Conclusion: Collectively our study demonstrates the potential of specific fusion proteins enabling mammalian cell production of tumor targeting protein domains for therapeutic development. Keywords: antibodies, recombinant protein expression, yeast library screening, scFv
